Earnings summaries and quarterly performance for 10x Genomics.
Executive leadership at 10x Genomics.
Board of directors at 10x Genomics.
Research analysts who have asked questions during 10x Genomics earnings calls.
Kyle Mikson
Canaccord Genuity
4 questions for TXG
Also covers: AKYA, BDSX, CSTL +12 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for TXG
Also covers: A, ALGN, AVTR +28 more
Patrick Donnelly
Citi
4 questions for TXG
Also covers: A, AVTR, BIO +21 more
Mason Carrico
Stephens Inc.
3 questions for TXG
Also covers: AKYA, CDNA, CSTL +13 more
Matthew Sykes
Goldman Sachs Group Inc.
3 questions for TXG
Also covers: A, ADPT, AVTR +21 more
Puneet Souda
Leerink Partners
3 questions for TXG
Also covers: A, ABCL, BRKR +20 more
Tejas Savant
Morgan Stanley
3 questions for TXG
Also covers: ADPT, AKYA, AVTR +19 more
Tycho Peterson
Jefferies
3 questions for TXG
Also covers: A, AVTR, BIO +22 more
Dan Arias
Stifel Financial Corp.
2 questions for TXG
Also covers: A, GH, ILMN +9 more
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
2 questions for TXG
Also covers: A, AVTR, CDXS +15 more
Daniel Brennan
TD Cowen
2 questions for TXG
Also covers: A, ADPT, AVTR +24 more
Douglas Schenkel
Wolfe Research, LLC
2 questions for TXG
Also covers: A, AVTR, BRKR +21 more
Luke Sergott
Barclays
2 questions for TXG
Also covers: A, AVTR, BRKR +19 more
Madeline Mollman
Wolfe Research, LLC
2 questions for TXG
Also covers: MRVI, PACB, TWST
Matthew Larew
William Blair & Company
2 questions for TXG
Also covers: AMED, ATR, DNA +10 more
Rachel Vatnsdal
JPMorgan Chase & Co.
2 questions for TXG
Also covers: A, AKYA, AVTR +11 more
Subhalaxmi Nambi
Guggenheim Securities
2 questions for TXG
Also covers: AKYA, BRKR, CSTL +15 more
Dan Brennan
UBS
1 question for TXG
Also covers: A, DHR, MDXH +7 more
Daniel Leonard
Stifel Financial Corp.
1 question for TXG
Also covers: A, AVTR, BIO +15 more
Jacob Krahenbuhl
William Blair
1 question for TXG
Also covers: MASS
Jaden
JPMorgan Chase & Co.
1 question for TXG
Kyle Boucher
TD Cowen
1 question for TXG
Also covers: LAB, MYGN, SEER +2 more
Lauren
Jefferies Financial Group Inc.
1 question for TXG
Also covers: NEO
Lu Li
Scotiabank
1 question for TXG
Also covers: FLGT, HOLX, MYGN +2 more
Matt Sykes
William Blair & Company, L.L.C.
1 question for TXG
Rachel Vatnsdal Olson
JPMorgan
1 question for TXG
Also covers: A, ADPT, AKYA +14 more
Salem Salem
Barclays
1 question for TXG
Also covers: GH, IQV, PACB +3 more
Thomas VonDerVellen
Guggenheim Securities, LLC
1 question for TXG
Also covers: NEO
Recent press releases and 8-K filings for TXG.
10x Genomics Discusses Strategic Positioning, Market Dynamics, and AI Opportunities at Wolfe Research Conference
TXG
Guidance Update
Product Launch
New Projects/Investments
- 10x Genomics (TXG) has undergone significant internal restructuring, including executive team changes and commercial reorganization, positioning the company to "play offense" as the macro environment potentially stabilizes.
- The company is actively managing pricing for single-cell consumables, particularly with the introduction of new product configurations like the Flex assay, to drive volume through market elasticity, aiming for a normalized pricing trend soon.
- TXG believes it is in a strong competitive position due to product performance, quality, and recent launches, effectively closing the price advantage previously leveraged by competitors.
- There is a growing interest in large-scale single-cell programs fueled by AI modeling, which TXG sees as a significant opportunity, with its technology being a key enabler for building these biological models.
- Due to the highly uncertain environment, 10x Genomics is not providing full-year guidance for 2026.
Nov 18, 2025, 4:20 PM
10x Genomics CEO Discusses Market Environment and Strategic Positioning
TXG
Management Change
Product Launch
Demand Weakening
- 10x Genomics underwent a major restructuring and executive team changes approximately a year ago, which has positioned the company to effectively navigate a challenging macro environment.
- The company's commercial restructuring, completed earlier this year, established specialized teams for CapEx instruments, biopharma, and academia, enhancing execution and adaptability despite ongoing market uncertainties, including funding and biopharma spending.
- 10x Genomics is strategically lowering single-cell consumable prices with new product configurations, such as the latest Flex assay, to drive volume and expand applications, anticipating continued volume growth and nearing a pricing equilibrium.
- The company is well-positioned competitively due to superior product performance, quality, and customer satisfaction, with recent product launches effectively addressing price as a competitive factor.
- There is a resurgence of interest in large-scale single-cell projects, driven by AI modeling, with 10x Genomics' technology being a key enabler for potential massive datasets that could transform drug discovery and science.
Nov 18, 2025, 4:20 PM
TXG CEO Discusses Strategic Positioning and Market Dynamics
TXG
Product Launch
New Projects/Investments
Demand Weakening
- 10x Genomics (TXG) CEO Serge Saxonov stated the company is in a strong position to "play offense" following a major restructuring and executive team changes, which have improved its ability to navigate a challenging macro environment.
- The company's strategy of lowering single-cell consumable prices through new product configurations, such as the recently launched Flex assay, is successfully driving volume growth and is expected to lead to a pricing equilibrium soon, enhancing competitive standing.
- There is a resurgence of interest in large-scale single-cell programs, which are being "turbocharged" by AI, creating significant opportunities for investment from biopharma, biotech, and academia to build large biological models.
- TXG maintains a strong competitive position due to product performance, quality, and breadth, and its sequencer-agnostic approach (compatible with Altima and upcoming Roche sequencers) offers superior value to customers.
Nov 18, 2025, 4:20 PM
TXG Reports Q3 2025 Results, Exceeds Revenue Guidance, and Provides Q4 Outlook
TXG
Earnings
Guidance Update
Product Launch
- TXG reported total revenue of $149 million for Q3 2025, exceeding the top end of its guidance range, though it was down 2% year-over-year.
- The company anticipates Q4 2025 revenue to be in the range of $154 million to $158 million.
- Spatial consumables revenue grew 19% year-over-year to $35.4 million, primarily driven by Xenium consumables.
- TXG began shipping the next generation of Chromium Flex and Xenium Protein in Q3 2025, with the latter allowing researchers to detect RNA and proteins in the same cell and tissue section.
- The company ended the quarter with $482 million in cash, cash equivalents, and marketable securities, and its operating loss improved to $32.2 million compared to $41.5 million in the prior year period.
Nov 6, 2025, 9:30 PM
10x Genomics Reports Q3 2025 Financial Results and Q4 2025 Revenue Guidance
TXG
Earnings
Guidance Update
Product Launch
- 10x Genomics reported revenue of $149.0 million for Q3 2025, representing a 2% decrease from the corresponding period of 2024 and a 2% sequential increase when excluding a one-time license and royalty revenue from Q2 2025.
- The company posted a net loss of $27.5 million and an operating loss of $32.2 million for Q3 2025, with a gross margin of 67%.
- As of September 30, 2025, cash and cash equivalents and marketable securities totaled $482.1 million, an increase of $35 million over the prior quarter.
- 10x Genomics expects Q4 2025 revenue to be in the range of $154 million to $158 million.
- The company launched new products, including the next-generation Chromium Flex and Xenium Protein, which enables simultaneous RNA and protein detection.
Nov 6, 2025, 9:08 PM
10x Genomics Reports Third Quarter 2025 Financial Results
TXG
Earnings
Guidance Update
Product Launch
- 10x Genomics reported Q3 2025 revenue of $149.0 million, representing a 2% decrease from Q3 2024, but a 2% sequential increase when excluding Q2 2025 one-time license and royalty revenue.
- The company's net loss for Q3 2025 improved to $27.5 million, compared to a net loss of $35.8 million in the corresponding prior year period, primarily due to a 10% decrease in operating expenses.
- Cash and cash equivalents and marketable securities increased by $35 million over the prior quarter, reaching $482.1 million as of September 30, 2025.
- For the fourth quarter of 2025, 10x Genomics expects revenue to be in the range of $154 million to $158 million.
Nov 6, 2025, 9:05 PM
10x Genomics Launches Next-Generation Flex Assay
TXG
Product Launch
- 10x Genomics (TXG) launched the next generation of its high-performance Flex assay, featuring automation-compatible plate-based multiplexing.
- This new assay delivers cost-effective, highly scalable single cell analysis, enabling researchers to profile up to 384 samples and 100 million cells per week using a 96-well plate format.
- The Flex assay supports modular usage, offering greater experimental flexibility and scale while reducing reagent waste, ultimately providing more data at a lower cost and extending single cell analysis to studies previously reliant on bulk methods.
- Early access customers, including the Allen Institute and Pfizer, have noted the assay's potential to accelerate drug discovery and transform the understanding of human health and disease by enabling the profiling of millions of cells at a fraction of the cost.
Oct 29, 2025, 1:00 PM
Countable Labs Launches Ten-Color PCR Platform and Appoints New CEO
TXG
Product Launch
CEO Change
- Countable Labs announced the launch of Countable 10, the first and only PCR platform capable of 10-color multiplexing, which extends the utility of its core Countable PCR technology.
- The Countable 10 platform builds on the highly sensitive Countable PCR technology, offering at least 10 times the sensitivity and precision of other PCR technologies.
- While the four-color Countable PCR platform is currently shipping, the 10-color Countable 10 is scheduled to ship in the first half of 2026.
- In conjunction with the launch, Giovanna Prout has been appointed as the new Chief Executive Officer of Countable Labs to accelerate commercialization.
Oct 7, 2025, 12:00 PM
Quarterly earnings call transcripts for 10x Genomics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more